重药控股参股创新药公司获辉瑞大单 最高约150亿元!

Core Viewpoint - Chongqing Yaoyou Pharmaceutical Co., Ltd. has signed a licensing agreement with Pfizer and Shanghai Fosun Pharmaceutical, granting Pfizer exclusive rights to develop, use, produce, and commercialize the oral small molecule GLP-1 receptor agonist YP05002 globally across all therapeutic areas for humans and animals [1][2]. Group 1: Financial Aspects - Yaoyou Pharmaceutical could receive up to $2.085 billion (approximately 15 billion RMB) from this agreement [2]. - Pfizer will pay an upfront non-refundable fee of up to $500 million, which includes an initial payment of $150 million and up to $350 million in milestone payments based on clinical trial and commercialization progress [2]. - Additionally, Pfizer will pay up to $1.585 billion in sales milestone payments based on the annual net sales of the licensed product, along with royalties calculated as a percentage of annual net sales [2]. Group 2: Product and Market Potential - YP05002 is an innovative GLP-1 receptor agonist developed by Yaoyou Pharmaceutical, aimed at treating type 2 diabetes, obesity, and related diseases by enhancing insulin secretion and reducing appetite [2][3]. - The potential indications for YP05002 include long-term weight management, type 2 diabetes, and non-alcoholic fatty liver disease [3]. - As of December 9, 2025, YP05002 is in Phase I clinical trials in Australia [3]. Group 3: Strategic Implications - The licensing agreement reflects recognition of Yaoyou Pharmaceutical's innovative research and development capabilities [3]. - This collaboration is expected to accelerate the clinical development and commercialization of the licensed product globally, potentially benefiting more patients worldwide [3].